Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Insulin-Like Growth Factor I. Found 5 abstracts

Fu J, Zhang J, Gong Y, Testa CL, Klein-Szanto AJ. Regulation of HIF-1 Alpha by the Proprotein Convertases Furin and PC7 in Human Squamous Carcinoma Cells. Molecular Carcinogenesis. 2015 Sep;54(9):698-706.   PMCID: 4101078
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul;32(19):2059-66.   PMCID: Pmc4067944
Ruggeri BA, Robinson C, Angeles T, Wilkinson Jt, Clapper ML. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res. 2002 Jan;8(1):267-74.
Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, Tricoli JV. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology. 2001 Oct;58(4):614-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Insulin-Like Growth Factor I

Insulin-Like Growth Factor I Male Aged metabolism drug therapy pathology genetics Drug Dose-Response Relationship Monoclonal Antibodies therapeutic use adverse effects Female Insulin-Like Growth Factor II Human Middle Aged administration & dosage Adult Receptor Protein-Tyrosine Kinases Pyrazines Risk Assessment Antineoplastic Combined Chemotherapy Protocols Furin Up-Regulation furin Negroid Race prevention & control Lung Neoplasms Prostatic Neoplasms diagnosis Tumor Cell Line Nude Mice Carboplatin Anticarcinogenic Agents Non-US Gov't Support Drug Administration Schedule Angiogenesis Inhibitors Hemangiosarcoma Paclitaxel Subtilisins Liver proprotein convertases Maximum Tolerated Dose Squamous Cell Carcinoma Treatment Outcome drug effects Insulin-Like Growth Factor Binding Protein 3 Vascular Endothelial Growth Factor A Growth Factor Receptors analysis Pathologic Neovascularization Middle Age methods Vascular Endothelium Neoplasms Neoplastic Gene Expression Regulation US Gov't Support-PHS Animal Head and Neck Neoplasms Cell Division blood supply Heterologous Transplantation Down-Regulation Rats RNA Interference Testosterone Pc7 Cultured Tumor Cells Glycosylated Hemoglobin A Antineoplastic Agents Pancreatic Ribonuclease Bispecific Antibodies HIF-1alpha regulation Kaplan-Meier Estimate alpha Subunit Hypoxia-Inducible Factor 1 blood pharmacokinetics Multivariate Analysis Small Interfering RNA Vascular Endothelial Growth Factor Receptors Biological Tumor Markers Disease-Free Survival cancer cells Signal Transduction Protein Biosynthesis antagonists & inhibitors Fibroblast Growth Factor Receptors Non-Small-Cell Lung Carcinoma Mice Oligonucleotide Array Sequence Analysis Caucasoid Race
Last updated on Monday, May 04, 2020